138 related articles for article (PubMed ID: 36513861)
21. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
22. 3D Coculture Models Underline Metastatic Melanoma Cell Sensitivity to Vemurafenib.
Morales D; Lombart F; Truchot A; Maire P; Hussein M; Hamitou W; Vigneron P; Galmiche A; Lok C; Vayssade M
Tissue Eng Part A; 2019 Aug; 25(15-16):1116-1126. PubMed ID: 30501565
[TBL] [Abstract][Full Text] [Related]
23. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.
De Paoli-Iseppi R; Johansson PA; Menzies AM; Dias KR; Pupo GM; Kakavand H; Wilmott JS; Mann GJ; Hayward NK; Dinger ME; Long GV; Scolyer RA
Pathology; 2016 Apr; 48(3):261-6. PubMed ID: 27020503
[TBL] [Abstract][Full Text] [Related]
24. Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
Lazow MA; Hoffman L; Schafer A; Osorio DS; Boué DR; Rush S; Wright E; Lane A; DeWire-Schottmiller MD; Smolarek T; Sipple J; Taggert H; Reuss J; Salloum R; Hummel TR; de Blank P; Pillay-Smiley N; Sutton ME; Asher A; Stevenson CB; Drissi R; Finlay JL; Fouladi M; Fuller C
Acta Neuropathol Commun; 2020 Nov; 8(1):182. PubMed ID: 33153497
[TBL] [Abstract][Full Text] [Related]
25. Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics.
Yan J; Wu X; Yu J; Ma M; Yu H; Xu T; Tang H; Xu L; Dai J; Si L; Chi Z; Sheng X; Cui C; Guo J; Kong Y
Melanoma Res; 2018 Dec; 28(6):527-535. PubMed ID: 30086074
[TBL] [Abstract][Full Text] [Related]
26. Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting.
Vanni I; Pastorino L; Tanda ET; Andreotti V; Dalmasso B; Solari N; Mascherini M; Cabiddu F; Guadagno A; Coco S; Allavena E; Bruno W; Pietra G; Croce M; Gangemi R; Piana M; Zoppoli G; Ferrando L; Spagnolo F; Queirolo P; Ghiorzo P
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901733
[TBL] [Abstract][Full Text] [Related]
27. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
[TBL] [Abstract][Full Text] [Related]
28. Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report.
Mordoh A; Triviño Pardo JC; Carri I; Barrio MM; Mordoh J; Aris M
BMC Med Genomics; 2023 Jan; 16(1):1. PubMed ID: 36604730
[TBL] [Abstract][Full Text] [Related]
29. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.
Yancovitz M; Litterman A; Yoon J; Ng E; Shapiro RL; Berman RS; Pavlick AC; Darvishian F; Christos P; Mazumdar M; Osman I; Polsky D
PLoS One; 2012; 7(1):e29336. PubMed ID: 22235286
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
31. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
Nassar KW; Hintzsche JD; Bagby SM; Espinoza V; Langouët-Astrié C; Amato CM; Chimed TS; Fujita M; Robinson W; Tan AC; Schweppe RE
Mol Cancer Ther; 2021 Oct; 20(10):2049-2060. PubMed ID: 34376578
[TBL] [Abstract][Full Text] [Related]
32. Personalized oncology and BRAF
Keller BA; Laight BJ; Varette O; Broom A; Wedge MÈ; McSweeney B; Cemeus C; Petryk J; Lo B; Burns B; Nessim C; Ong M; Chica RA; Atkins HL; Diallo JS; Ilkow CS; Bell JC
J Cancer Res Clin Oncol; 2021 May; 147(5):1365-1378. PubMed ID: 33555379
[TBL] [Abstract][Full Text] [Related]
33. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
[TBL] [Abstract][Full Text] [Related]
34. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
[TBL] [Abstract][Full Text] [Related]
35. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.
Hendricks WPD; Zismann V; Sivaprakasam K; Legendre C; Poorman K; Tembe W; Perdigones N; Kiefer J; Liang W; DeLuca V; Stark M; Ruhe A; Froman R; Duesbery NS; Washington M; Aldrich J; Neff MW; Huentelman MJ; Hayward N; Brown K; Thamm D; Post G; Khanna C; Davis B; Breen M; Sekulic A; Trent JM
PLoS Genet; 2018 Sep; 14(9):e1007589. PubMed ID: 30188888
[TBL] [Abstract][Full Text] [Related]
36. Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines.
Woo XY; Srivastava A; Graber JH; Yadav V; Sarsani VK; Simons A; Beane G; Grubb S; Ananda G; Liu R; Stafford G; Chuang JH; Airhart SD; Karuturi RKM; George J; Bult CJ
BMC Med Genomics; 2019 Jul; 12(1):92. PubMed ID: 31262303
[TBL] [Abstract][Full Text] [Related]
37. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
38. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
[TBL] [Abstract][Full Text] [Related]
39. Establishment and genetically characterization of patient-derived xenograft models of cervical cancer.
Zou S; Ye M; Zhang JA; Ji H; Chen Y; Zhu X
BMC Med Genomics; 2022 Sep; 15(1):191. PubMed ID: 36076209
[TBL] [Abstract][Full Text] [Related]
40. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]